About Us
Clinical Advisory Board
GreenJay has assembled a world-class Clinical Advisory Board consisting of experts in bone
marrow/stem cell transplants, both for adults and children. These members represent a diverse
geographical presence and will serve as mentors as GreenJay advances Bulanta through the
regulatory approval process.
Borje S. Andersson, PhD, Chair, Clinical Advisory Board.
See Leadership for more Information
Didier Blaise, M.D.
Dr. Blaise is Professor of Hematology at Aix-Marseille University and former Head of the Department of Hematology. H has also served as founding head and Director of the Transplant and Cellular Immunotherapy program at Institut Paoli-Calmettes, Marseille, which at his retirement was recognized as one of the largest and most innovative transplant programs in the European Union. Dr. Blaise also serves as an Advisory Professor at the Jiao Tong University, Shanghai, China, and visiting Professor at Zhejiang University, Hangzhou, China. Professor Blaise is a past president of the French Society of Bone Marrow and Cell Therapies, the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Because of his contributions to the transplant field, Dr. Blaise has been recognized with the Lifetime Achievement Award in acute Leukemia from the European Society of Blood and Marrow Transplantation (EBMT), and an EBMT Honorary Membership Award. He has authored more than 770 peer-reviewed articles, cited more than 40,000 times. His research currently focuses on optimizing allogeneic stem cell transplantation as therapy for malignant and genetic diseases.
Mohamad Mohty, M.D., PhD
Dr. Mohty is a full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team (Inserm) at the Saint-Antoine Research Centre in Paris.
Dr. Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and past chairman of the Acute Leukemia Working Party of the EBMT . He is also the founder and current chairman of the International Academy for Clinical Hematology (IACH) and executive board member of the Intergroupe Francophone du Myelome (IFM). Dr. Mohty is also a fellow of the French National Academy of Medicine. In 2021, he was knighted as “chevalier de la légion d’honneur” (The Legion of Honor).
In addition to publishing more than 1000 peer-reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr. Mohty also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International. He also serves as an editor, board member, and/or reviewer across numerous other reputable journals.
Dr. Marcos J. G. de Lima, M.D.
Dr. de Lima is Professor of Medicine, Ohio State University in Columbus, Ohio, and Director of The Blood and Bone Marrow Transplant and Cellular Therapy Program at the Ohio State James Hospital. He has extensive experience developing and conducting clinical trials in the context of hematopoietic stem cell transplantation for myeloid malignancies and in cellular therapy. His research focus on strategies to expand utilization of allogeneic transplantation, in the prevention of leukemia relapse after transplant, and the development of novel cellular therapies and novel cellular manufacturing processes.
Jaap Jan Boelens, M.D., PhD
Dr. Boelens is a Professor of Pediatrics and Chief of the Pediatric Stem Cell Transplant and Cellular Therapy Service at Memorial Sloan Kettering Cancer Center, and a Professor of Pediatrics at Weill Cornell Medical College of Cornell University in New York, NY since 2018.
He previously served as an attending physician at the University Medical Center Utrecht, and the Princess Maxima Center for Pediatric Oncology, where he built the largest pediatric cord blood cell transplantation program in Europe. He is currently serving as a VP for North America of the International Society for Cell and Gene Therapy. His main clinical focus is on using stem cell transplantation as a cure for genetic diseases, but he is also focusing on studying the regulation of the immune system to treat malignant diseases such as leukemia and lymphomas. Dr. Boelens has published extensively on how to properly use pharmacokinetics and pharmacodynamics to optimize treatment, using drugs like busulfan, nucleoside analogs and antithymocyte globulin to both maximize antitumor effects and to avoid toxicities, including but not limited to, liver toxicity and graft vs host disease. The trail-blazing research by Dr. Boelens and his group is published in high-profile journals like Blood, Blood Advances, Lancet and New England Journal of Medicine.
Suradej Hongeng, M.D.
Dr. Hongeng is a Professor of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Vice Dean of Special Affairs, and Chief of Excellence for Cell Therapy and Gene Therapy, Mahidol University, Bangkok, Thailand.
He received his M.D. degree at Ramathibodi Hospital, Mahidol University, followed by pediatric residency training at University of Illinois at Chicago and a pediatric hematology-oncology fellowship at St Jude Children’s Research Hospital, Memphis, TN.
To date, Dr. Hongeng has published more than 331 peer-reviewed publications listed in Scopus with H-index 41. His clinical experience in hematopoietic stem cell transplantation, especially in pediatric patients, encompasses almost 1,000 patients over the past 28 years, and among his most noteworthy contributions are those applied to highly mismatched donor-transplant for patients with genetic diseases, where he increased the 5-year survival of such patients from less than 50% to currently over 95%. His research interests are focused on hematopoietic stem cell transplantation using highly mismatched, aka haploidentical, transplantation with post-transplant cyclophosphamide-based graft vs host disease prophylaxis in malignant and non-malignant diseases, especially thalassemia. He is also involved with developing gene therapy approaches, e.g. CAR T-cell therapy, and gene therapy for thalassemia, and other genetic diseases, as well as for HIV.
Dr. Hongeng has several patents pertaining to CAR T-cell therapy, thalassemia, Gaucher disease,
circular mRNA and several small molecules for study and treatment of hematologic diseases. Because of his contributions to the field of Hematology and transplantation he has received several national scientific awards, and he is recognized among the Top 1% medical researchers of Mahidol University.